Knee gel injection trial pulled before it began
NCT ID NCT06839222
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether a new gel called Hydrogel OA 2% could safely relieve knee osteoarthritis pain better than a standard treatment. It planned to enroll adults with knee OA and give them one injection, then track side effects and symptom improvement for 26 weeks. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydrogel OA 2% (a gel made from bovine gelatin and cellulose nanocrystals)
What this could lead to
If it had worked, this could have pointed toward a new injection to ease knee pain and improve function in osteoarthritis.
What could go wrong
The trial was withdrawn before enrolling anyone, so no data on safety or effectiveness exist. Early-stage device studies often fail to show benefit or may have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS (KNEE OA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ DELTA
Roeselare, Belgium
-
AZ Sint Jan Brugge
Bruges, Belgium
-
CHU Liège
Liège, Belgium
-
More Institute
Antwerp, Belgium
-
UZ Antwerpen
Edegem, Belgium